To be 'good' something must operate consistently with the laws of reality and contribute to the evolution of the whole; that is what is most rewarded.

Pipeline

CanVirex posesses a highly valuable portfolio of measles virus vectors for cancer immunotherapy. The lead candidate for the oncology program (CanVirex01) is pre-clinically fully developed and initiation of clinical testing is anticipated in 2024.

Along with the strategic research alliance with the Heidelberg University Hospital, CanVirex constantly screens potential vector candidates that can be added to the existing portfolio.

The established biomarker program routinizes testing of molecular signatures and predictive biomarkers. This program will be run in parallel to clinical trials. Identification of biomarkers is essential for providing patient-specific treatment options.

Discovery

Pre-clinical

Clinical

CanVirex01
CanVirex02
CanVirex03
CanVirex04
Biomarker program